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Abstract 
Membrane-associated phosphoinositide-phospholipase C (PI-PIX),B (150 kDa) and its truncated forms (100 kDa and 45 kDa) were purified from 
human platelets. The 100 kDa PI-PI&8 was found to be activated to a greater extent by brain G-protein br subunits compared to the intact 150 
kDa enzyme. Furthermore, treatment withy-calpain of the intact PI-PIX,B (150 kDa) caused a marked augmentation of its activation by& subunits. 
This enhanced PLC activation by /3r subunits was due to truncation by p-calpain, producing a 100 kDa PI-PLC, but not by another protease, 
thrombin. 
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1. Introduction 
Phosphoinositide-specific phospholipase C (PI-PLC) 
is a key signal transducing enzyme generating two sec- 
ond messengers, inositol trisphosphate and diacylglyc- 
erol [l]. There are three types @, y, 6) containing nine 
distinct subtypes [2,3]. It is established that the PI-PLC-y 
type is activated by tyrosine kinases [2,4], while the PI- 
PLC-p type is regulated by interaction with G- proteins 
in two distinct ways; one through c1 subunits of the Gq 
family, which is insensitive to pertussis toxin (PT). and 
the other through the /?y subunits of PT-sensitive G- 
proteins [S-8]. 
It has been shown in human platelets that multiple 
forms of PI-PLC are present in cytosol and membrane 
fractions containing PLC-B, yl, y2 and 6 [9,10]. We 
previously indicated that membrane-associated platelet 
PI-PLC activity was stimulated by either GTPyS-acti- 
vated Gi or Go to nearly the same extent [l 11. This and 
other findings [7,8] lead us to suggest hat By subunits 
of heterotrimeric G-proteins may be involved in the PI- 
PLC activation in human platelets. In order to gain fur- 
ther insight into the PI-PLC activation by G-protein in 
*Corresponding author. Fax: (81) (582) 65-9002. 
Abbreviations; PI-PIX, phosphoinositide-specific phospholipase C; 
PIP*, phosphatidylinositol4,5-bisphosphate; G-protein, guanine nucle- 
otide-binding regulatory proteins; PT, pertussis toxin. 
human platelets, we have purified the membrane-associ- 
ated PI-PLC that was activated by brain G-protein By 
subunits and demonstrated that truncation of the PI- 
PLC by p-calpain much enhanced its activation by G- 
protein By subunits. 
2. Materials and methods 
2.1. Materials 
PIP, (bovine brain) and phosphatidylethanolamine (bovine brain) 
were obtained from Sigma Chemical Co. [‘H]PIPZ (specific activity, 8.0 
Ci/mmol) was from Du Pont-New England Nuclear. y-Calpain (por- 
cine erythrocyte, 120 U/mg protein) and diisopropyl fluorophosphate 
were from Nacalai Tesque (Kyoto). E-64 was from Peptide Institute 
Inc. (Osaka). 
2.2. PuriJication procedures 
The membrane-associated PI-PI@ was purified from outdated 
human platelet concentrates as described previously [121. The G-protein 
pr subunits from bovine brain were purified as outlined in [13]. 
2.3. Assay for PI-PLC activity and activation by G-protein Pr subunits 
PI-PLC activity was determined as described previously [9], using 
[3H]PIP, (18,000 dpm)/PIP, (0.1 mM)IPE (1.0 mM) as substrate. The 
activation of PI-PIX by G-protein /3r subunits was evaluated as de- 
scribed by Smrcka and Sternweis [14]. The reaction mixture (60 ~1) 
contained 50 mM Na HEPES (pH 7.2), 0.17 mM EDTA, 3 mM EGTA. 
1 mM dithiothreitol, 17 mM NaCI, 67 mM KCl, 0.83 mM MgCI,, 1.5 
mg/ml bovine serum albumin and 1.5 mM CaCl, to give 100 nM free 
Ca*’ concentration. The bovine brain G-protein /3r subunits were sol- 
ubilized in 0.3% octyl B-o-glucopyranoside (final concentration, 
0.05%). 
2.4. Western blot analysis 
Western blot analysis of the PI-PLC was performed using polyclonal 
antisera raised against PI-PIX-/3 which was kindly supplied by Dr. T. 
0014-5793/94/$7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
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Takenawa (Institute of Medical Science, University of Tokyo) and 
monoclonal antibody of PL-PLC-/?I by Dr. S.G. Rhee (NIH, 
Bethesda) 
2.5. Proteolytic truncation of platelet PI-PLC-p by I-calpain 
The purified membrane-associated platelet PI-PLC,B (150 kDa) was 
incubated with 0.2 U ofp-calpain in a 30~1 reaction mixture containing 
50 mM HEPES (pH 7.2), 1 mM dithiothreitol, 3 mM EGTA, and 4 mM 
CaCI, at 30°C. At the indicated times, the reaction mixture (5 ~1) was 
removed and added to 50 ~1 of 3 mM EGTA solution containing 1 pg 
of E-64 in order to terminate proteolysis. 
3. Results 
A membrane-associated PI-PLC was purified from 
human platelets as described previously [12]. When sub- 
jected to five steps of column chromatographies (Q 
Sepharose, heparin-Sepharose, Ultrogel AcA-44, hy- 
droxyapatite, and Mono Q), a PI-PLC preparation thus 
obtained revealed two major polypeptide bands (150 
kDa and 60 kDa) on SDS-polyacrylamide gel by silver 
stain (Fig. IA, lane 1). The polypeptide with 150 kDa 
cross-reacted with the polyclonal antibody raised against 
PI-PLC-/3 fragments, but 60 kDa polypeptide did not 
(Fig. lB, lane 1). Further purification of the 150 kDa 
PI-PLC-B fraction by TSKgel-3000 column chromatog- 
raphy produced a single protein peak corresponding to 
PLC activity. But when this PLC activity peak was sub- 
jected to SDS-PAGE, it ran as 100 kDa and 45 kDa 
polypeptides (Fig. IA, lane 2). These results suggest hat 
nicking occurred at the region between the 100 kDa and 
45 kDa polypeptides of the purified 150 kDa PI-PLC-/I. 
These 100 kDa and 45 kDa polypeptides cross-reacted 
with the polyclonal anti-PI-PLC-/I antibody (Fig. lB, 
lane 2), which were thought to be produced by trunca- 
tion of the intact 150-kDa polypeptide. The 150 kDa and 
100 kDa PI-PLC-p forms showed similar catalytic prop- 
erties in substrate specificity for PI- and PIP,-hydrolysis, 
but the 45 kDa polypeptide showing cross-reactivity with 
the polyclonal anti-PI-PLC-/I antibody had no catalytic 
activity (data not shown). Furthermore, effects of brain 
G-protein /?y subunits on the PIP,-hydrolyzing activities 
of the intact and the truncated PI-PLC-/3 were examined. 
As shown in Fig. lC, two PI-PLC-/? fractions (PLC-1 
with intact 150-kDa polypeptide; PLC-2 with truncated 
lOO-kDa polypeptide) were activated to different extents 
by the brain G-protein By subunits. At 400 nM of /?y 
subunits, the truncated 100 kDa PI-PLC-/I activity was 
enhanced to a much greater extent (27-fold) compared 
to the intact 150 kDa enzyme exhibiting only a 6-fold 
increase. 
To determine whether proteolytic cleavage of the 150 
kDa PI-PLC-/3 to the 100 kDa form was responsible for 
the marked activation by /?y subunits, the PI-PLC-/3 (150 
kDa) was subjected to proteolysis catalyzed by P-Cal- 
pain. Upon incubation with various concentrations of 
p-calpain, the extents of activation of the PI-PLC-/I by 
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Fig. 1. SDS-PAGE and immunoblot of platelet membrane-associated 
PI-PLC. The purified membrane-associated PI-PLC fractions were sub- 
jected to SDS-polyacrylamide gel (8%) electrophoresis and proteins 
were detected by silver staining (A) and by immunostaining with poly- 
clonal anti-PLC-B antibody (B). Lanes 1. membrane PI-PLC obtained 
by Mono Q column chromatography; lanes 2, membrane PI-PLC ob- 
tained by TSKgel 3000 column chromatography. Arrows indicate M, 
standards (from top); 212 kDa (myosin), 170 kDa (qmacroglobulin), 
116 kDa @I-galactosidase), 76 kDa (transferrin), 53 kDa (glutamic 
dehydrogenase). (C) Activation of the purified membrane-associated 
PI-PLCs by brain G-protein /$J subunits. The PI-PLC activities were 
measured with different amounts of brain G-proteinBy subunits under 
the conditions described in section 2. PLC-1, intact PI-PLC fraction 
shown in Fig. 1 A, lane 1; PLC-2, truncated PI-PLC fraction shown in 
Fig. lA, lane 2. Results represent mean + S.D. from three determina- 
tions. 
By subunits were elevated in dose- (Fig. 2A) and time- 
(Fig. 2B) dependent manner. When the 150 kDa PI-PLC- 
/I preparation was subjected to gel filtration on a Super- 
ose 12 column, a single PIP,-hydrolyzing activity peak 
was eluted at the position of approx. 290 kDa, indicating 
a dimer form in the native state. After treatment with 
p-calpain (0.2 pug) for 30 min, the activity was eluted at 
the position of approx. 110 kDa, suggesting that the 
higher A4, form of PI-PLC-/I (150 kDa) was converted 
to the lower M, form (100 kDa) by p-calpain. The aug- 
mented activation of PI-PLC-p by /?y subunits was due 
to proteolytic modification by p-calpain, but not by an- 
other protease thrombin (Fig. 3). 
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4. Discussion 
In this paper, we have demonstrated that the truncated 
100 kDa PI-PLC-/I form purified from human platelet 
membranes was activated to a much higher extent by 
brain G-protein /3y subunits compared to the intact PI- 
PLC-/I (150 kDa). It has been reported that the PI-PLC- 
/I1 was activated by Gqa family and its truncated 100 
kDa enzyme produced by calpain could not be activated 
by Gqa [15]. Furthermore, most recently, Blank et al. 
[ 161 showed that a 110 kDa PI-PLC purified from brain 
cytosol which was identified to be a truncated form of 
PI-PLC-/?3, showed extremely higher activation by /?y 
subunits but was not affected by Gqa. Lee et al. [17] 
indicated that the PI-PLC-/I2 mutants which lack the 
carboxyl-terminal were activated by By subunits but not 
by Gqa. These results suggest hat /3y subunits could 
activate PI-PLC-/I by interacting at distinct site from that 
of the Gqol. We have previously purified a cytosolic 100 
kDa PI-PLC-B which exhibited similar catalytic proper- 
ties to those of the membrane 100 kDa PI-PLC-/3 [12]. 
Moreover, it was demonstrated that the truncated 100 
kDa PI-PLC-/?l purified from bovine brain membrane 
was activated by the brain G-protein /3y subunits to a 
lower extent (two-fold) as compared to the platelet 100 
kDa PI-PLC-B showing a 30- to 40-fold activation (data 
not shown). Therefore, it might be predicted that the 
human platelet PI-PLC-/I enzymes responsible for acti- 
vation by By subunits could be of the 83 subtype. 
There are many studies indicating that calpain activa- 
tion and cleavage of specific endogenous protein sub- 
strates, such as cytoskeletal proteins, are correlated with 
physiological events including microvesicle shedding, cy- 
toskeletal rearrangement, secretion or clot retraction in 
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Fig. 2. G-proteinj?y subunits-dependent activation ofp-calpain-treated 
PI-PLC-j?. The 150 kDa PI-PLC-jr fraction was incubated for 30 min 
with different amounts (A) of p-calpain under the conditions as de- 
scribed in section 2. At the indicated times (B), 5 ~1 of reaction mixture 
were removed and added to 50~1 of a 3 mM EGTA solution containing 
1 pg E-64. Aliquots (20~1) of this reaction mixture were then incubated 
at 37°C for 10 min in a final volume of 60 ~1 of PI-PLC assay mixture 
with or without G-protein Br subunits (200 nM). Results represent 
mea&SD. from three determinations from two similar experiments. 
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Fig. 3. Enhancement of/IT-dependent activation of PI-PLC-j? by prote- 
olytic truncation. The 150 kDa PI-PLC-/I fraction was incubated with 
0.2 fig ,rf-calpain or 1 PM thrombin in the reaction mixture (30 ~1) 
containing 3 mM EGTA or 1 mM Ca*’ for 30 min at 30°C and then 
added to 50 ~1 of 3 mM EGTA solution containing 1 pg E-64 and 0.1 
mM diisopropyl fluorophosphate. Aliquots (20 ~1) of this reaction 
mixture were incubated in the PI-PLC assay mixture (total 60 ~1) with 
or without G-protein j?r subunits (200 nM) at 37°C for 10 min. The 
results are expressed as % increase in PI-PLC activity obtained in the 
presence of G-protein pr subunits. Results are mean of three determi- 
nations from two similar experiments. 
human platelets [l&19]. Furthermore, recent reports 
have shown that ~~60”” [20] and protein phosphoty- 
rosine phosphatase 1B [21] were also endogenous ub- 
strates for calpain in platelet activation. It has also been 
reported that calpain translocates from cytosol to mem- 
brane and activates itself via autolysis which is promoted 
by polyphosphoinositides at physiological calcium con- 
centration [22]. Moreover, the results of calpain inhibi- 
tion in thrombin-activated human platelets implied that 
calpain may play a role in platelet activation through a 
PI-PLC activation [23]. Since platelet PI-PLC is known 
to be a good substrate for calpain [24] it is conceivable 
that membrane-associated PI-PLC-/I is positively regu- 
lated by /3y subunits via a limited proteolysis by calpain. 
To prove this hypothetical view, further investigations 
are required to examine whether truncation of PI-PLC-/I 
by calpain occurs in platelet activation in vivo. 
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